SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs
9/2/2014 1:47:41 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (NASDAQ: SAGE) today presented preclinical data on its second-generation neuroactive steroid, SAGE-217, at the Twelfth Eilat Conference on New Anti-Epileptic Drugs in Madrid, Spain. The data suggest improved activity for this compound versus other first-generation neuroactive steroids in development, as well as favorable selectivity and pharmacokinetic profile of the drug.
Help employers find you! Check out all the jobs and post your resume.
comments powered by